Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes

ABSTRACT

To determine whether exenatide is effective in reducing weight and glycosylated hemoglobin level [HbA1c], and to investigate its efficacy in improving lipid profile, blood pressure, and creatinine levels in the Arab population. This study was conducted at the Endocrine Unit, Dubai Hospital, Dubai, United Arab Emirates. We retrospectively collected data from patients with type 2 diabetes started on exenatide between November 2011 and February 2012. Data included demographics, clinical, laboratory results, and medications used. A general linear model adjusted by baseline characteristics [weight, HbA1C, age, use of statins, and duration of diabetes] was used to assess changes between baseline and end of trial in HbA1C, weight, low density lipoprotein cholesterol, total cholesterol, triglycerides, creatinine, and blood pressure. After 6 months of treatment with exenatide, the HbA1c decreased by 0.47% [95% confidence level [CI] -0.01 - 0.95] [p=0.055]. Weight reduction was highly significant; 5.6 kg [95% CI 3.34 - 7.85] [p<0.001]. Those reductions remained significant after adjustment for confounding factors. This study showed that weight reduction was highly significant with exenatide. The borderline significance in HbA1c reduction can be attributed to the small sample size